摘要
多年来,核苷酸代谢一直被用于各种临床环境,包括癌症。 在过去几年中积累的参与这种代谢和相关细胞过程的某些酶的知识增加,提供了与某些蛋白质的成药性和其他蛋白质的抑制剂使用相关的重要信息。 在这里,我们回顾了对药物开发有重大兴趣的此类酶的最新数据,即 SAMHD1 和 NUDIX 家族的蛋白质。 其中包括关于它们在癌症进展中的作用、与癌症患者临床结果的相关性以及酶抑制剂的开发和研究的信息。
关键词: NUDIX、MTH1、SAMHD1、癌症、治疗、抑制剂。
Current Medicinal Chemistry
Title:Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Volume: 28 Issue: 21
关键词: NUDIX、MTH1、SAMHD1、癌症、治疗、抑制剂。
摘要: Nucleotide metabolism has been targeted for many years and in various clinical settings, including cancer. The increased knowledge of certain enzymes involved in this metabolism and associated cellular processes accumulated over the last few years, gives important information related to the druggability of certain proteins and the use of inhibitors for others. Here, we review recent data on such enzymes with a major interest in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include information on their roles in cancer progression, correlations with clinical outcomes in cancer patients, and the development and study of enzymatic inhibitors.
Export Options
About this article
Cite this article as:
Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867328666201125120422
DOI https://dx.doi.org/10.2174/0929867328666201125120422 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Current Trends and Future Directions of Fluoroquinolones
Current Medicinal Chemistry Xanthone Derivatives: New Insights in Biological Activities
Current Medicinal Chemistry Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Controversies of Androgen Ablation Therapy for Metastatic Prostate Cancer
Current Pharmaceutical Design Advances in Gene Therapy for Bladder Cancer
Current Gene Therapy Exogenous Expression of WNT7A in Leukemia-Derived Cell Lines Induces Resistance to Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Therapeutic Applications of Capsaicin in Upper Airways
Current Drug Targets Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Cell Death in Mammalian Development
Current Pharmaceutical Design G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Clinical Use of Therapies Targeting Tumor Vasculature and Stroma
Current Cancer Drug Targets New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
Current Medicinal Chemistry Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery